Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DaVita, Inc. (NYSE:DVA ) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET Company Participants Javier Rodriguez - CEO & Executive Director Joel Ackerman - CFO & Treasurer Conference Call Participants Andrew Mok - UBS Philip Chickering - Deutsche Bank Gary Taylor - Cowen and Company Kevin Fischbeck - Bank of America Merrill Lynch Operator Good evening. My name is Michelle, and I will be your conference facilitator today.

DaVita, Inc. (DVA) Q4 2022 Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 26.14% and 0.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Q4 Earnings Beat Estimates

DENVER , Feb. 22, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2022. "We continue to have excitement and conviction in our long-term capabilities and strategy to differentiate DaVita as a healthcare provider and employer of choice," said Javier Rodriguez, CEO of DaVita Inc. "I am encouraged by the operating progress we have made in recent months, and we will be closely monitoring volume and the labor environment which remain challenges in 2023.

DaVita Inc. 4th Quarter 2022 Results

Apple

American Express

Bank of America

General Motors

Kraft Heinz

Coca-Cola

Moody's

Taiwan Semiconductor Manufacturing

Visa

VeriSign

Verizon

Warren Buffett is increasingly willing to dump his lousy stocks. But there's a group of beloved S&P 500 stocks he won't sell.

Warren Buffett Refuses To Part With 21 Beloved Stocks

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: DaVita HealthCare (DVA) Q4 Earnings Expected to Decline

Moderna

VanEck Vectors Pharmaceutical ETF

Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow. Passive investors seeking a defensive position might just purchase the VanEck Pharmaceutical ETF and call it a year.

Betting On Biotech

Bank of New York Mellon

Paramount Global

When it comes to Warren Buffett stocks to buy, the quintessential purchase is Berkshire Hathaway (NYSE: BRK-B ). After all, when you buy shares in Berkshire, you not only get a bunch of great operating businesses like BNSF Railway, Geico, Berkshire Energy and so many more, but you also get an equity portfolio currently worth more than $350.5 billion.

The 7 Best Beaten-Down Warren Buffett Stocks to Buy

DENVER , Feb. 1, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter and full year results on Wednesday, February 22, 2023, at 5:00 p.m. Eastern Time.

DaVita Inc. Schedules 4th Quarter 2022 Investor Conference Call

Company highlights major milestones achieved over the past year DENVER , Jan. 31, 2023 /PRNewswire/ -- Today, DaVita recognizes the impact its employees, known as teammates, had on kidney care in 2022. Over the last year, DaVita made strides in innovation and clinical excellence while uplifting the communities it serves.

DaVita Emphasized Holistic Care for Kidney Patients and Teammates in 2022

Paycom Software

Warner Bros Discovery Inc

If you're thinking about which stocks to sell heading into 2023, you might want to start with companies whose CEOs are overpaid. The Financial Times published an article in mid-December discussing how to pay executives in the age of stakeholder capitalism.

Sell These 3 Stocks and Kick These Overpaid CEOs Out of Your Portfolio

The event has raised nearly $15 million for the nonprofit since 2007, enabling Bridge of Life to enhance kidney care globally through its medical missions. DENVER , Dec. 20, 2022 /PRNewswire/ -- Today, DaVita announced that over 4,400 DaVita teammates, friends, family and key members of the kidney care community joined together to participate in the inaugural Move It with Purpose (MIWP) event to benefit Bridge of Life, a nonprofit founded by DaVita to support the prevention and treatment of chronic disease.

DaVita's Move It with Purpose Event Raises Funds for Bridge of Life

Investors need to pay close attention to DaVita (DVA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in DaVita (DVA) Stock?

BRK has held shares in DVA since 2011, presumably picked by Ted Weschler. Debt levels have risen but the company has strong FCF and a track record of paying down debt aggressively when needed.

DaVita: A Favorite Of Berkshire Investment Manager Is Undervalued

Healthcare stocks have been strong recently and for the year amid heightened volatility. One healthcare provider has dealt with an unfavorable SCOTUS ruling and a big EPS miss in recent months.

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution

Ally Financial

Amazon

Celanese

Charter Communications

Floor & Decor Holdings

Liberty Latin America Ltd.

Nu Holdings

Snowflake

StoneCo

Most S&P 500 stock investors own a few turkeys this year. And Warren Buffett is no exception.

These Are Warren Buffett's 12 Biggest Stock Mistakes This Year

Liberty Media Corp-Liberty SiriusXM

Occidental Petroleum

Which are these big Buffett bets are the best picks for investors?

Warren Buffett Now Owns 20% or More of These 5 Companies

AMN Healthcare Services

HCA Healthcare

U.S. market indexes were all down the morning after Election Day, with the outcome of several key races still too close to call as Americans weigh their priorities on health care, education, border security and the state of the economy, among other concerns.

3 Undervalued Predictable Health Care Stocks to Put Under the Microscope

This year's research centered on advancements in kidney transplantation and equity in patient care DaVita addresses equitable access to breakthrough trials and decentralized research by introducing new Chronic Kidney Disease & Rare Disease Network DENVER , Nov. 3, 2022 /PRNewswire/ -- DaVita Clinical Research (DCR) will highlight its latest research during the American Society of Nephrology (ASN) Kidney Week, being held in Orlando from November 2-6, 2022. "We look forward to Kidney Week as a crucial inflection point to socialize new discoveries and advancements that are changing the lives of patients," said Dr. Steven Brunelli, vice president of health economics and outcomes research for DaVita.

DaVita Clinical Research Showcases Chronic Kidney Disease and Rare Disease Network, Presents New Research Findings at Kidney Week 2022

DaVita Inc. (NYSE:DVA ) Q3 2022 Earnings Conference Call October 28, 2022 8:30 AM ET Company Participants Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - UBS Kevin Fischbeck - Bank of America Pito Chickering - Deutsche Bank Justin Lake - Wolfe Research Operator Good morning. My name is Amanda, and I will be your conference facilitator today.

DaVita Inc. (DVA) Q3 2022 Earnings Call Transcript

Shares of DaVita Inc. plummeted in active trading Friday, toward their worst performance in more than two decades, after the dialysis company reported third-quarter that fell well below expectations and slashed its full-year outlook, citing declining treatments and rising labor costs.

Dialysis company DaVita stock suffering worst day in 22 years after big profit miss, disappointing outlook

DaVita's (DVA) Q3 performance gets a boost from strength in both its segments.

DaVita (DVA) Q3 Earnings Lag Estimates, 2022 EPS View Cut

DaVita says full-year profit is now expected to be in the range of $6.20 to $6.70 a share, lower than the company's prior range of $7.50 to $8.50.

DaVita Stock Plummets Most Since 2000 on Outlook Cut

Pinterest

Friday's market action saw volatility both upward and downward.

2 Market-Moving Stocks You Can't Afford to Ignore

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.12% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Q3 Earnings and Revenues Lag Estimates

DENVER , Oct. 28, 2022 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2022. "The third quarter was a challenging quarter for us.

News for DaVita Stock (DVA)